Journal: Marine Drugs
Article Title: Initial Exploration of the In Vitro Activation of GLP-1 and GIP Receptors and Pancreatic Islet Cell Protection by Salmon-Derived Bioactive Peptides
doi: 10.3390/md22110490
Figure Lengend Snippet: Figure 5. Normalized mean level of GIP receptor activity measured by changes in intracellular cAMP levels. Results are expressed as the fluorescence intensity (arbitrary units/a.u.) of the red cAMP-Nomad biosensor. Each of the six conditions was analyzed in three independent experiments (three replicates per experimental group, n = 3), making a total of eighteen assessments. Data points represent the mean ± standard deviation for each test condition. GIP agonist dose of 1 µM is equivalent to 0.004 mg/mL. * Indicates a p-value of <0.05, and ** indicates a p-value of <0.01 compared to PBS negative control.
Article Snippet: The test compound, SPH, was assessed against positive controls, a standard GLP-1 receptor agonist (Sigma-Aldrich H6795) and a standard GIP receptor agonist (Tocris, Minneapolis, MN, USA, 2257), both at a concentration of 1 μM (ca.
Techniques: Activity Assay, Fluorescence, Standard Deviation, Negative Control